Le Lézard
Classified in: Health, Covid-19 virus
Subjects: SVY, PSF

airPHX Breakthrough Technology Available to Address Coronavirus and Global Catastrophic Biological Risks


MCLEAN, Va., Jan. 27, 2020 /PRNewswire/ -- An independent testing lab has confirmed that airPHX ("air fix") proprietary non-thermal plasma technology is highly effective in protecting populations with potential exposure to the coronavirus (2019-nCoV).  airPHX technology can be scaled to treat air and surfaces in large facilities including hospitals, hotels, schools, airports and other public areas.  Independent lab testing has validated over 4 log reductions in surface viruses and antibiotic resistant bacteria in 30 minutes on surfaces with corresponding reductions in airborne organisms.  Deployment of airPHX technology in U.S. hospitals has resulted in 95% reductions in airborne and surfaces organisms in active patient environments, including clinical data supporting dramatic reductions in healthcare-associated infections. 

For More Information: https://www.airPHXhealth.com.

Coronavirus and Global Catastrophic Biological Risks

Antimicrobial resistant pathogens pose challenges to public health because they are difficult to detect until active cases begin to present, with risk increasing along with lengthy incubation periods.  Detection can be further delayed when cases are not immediately associated with the emergence of a particular virus.  Existing methods to address GCBRs include ineffective respiratory masks, expensive and dangerous cleaning chemicals, and isolation of suspected infected people.  These risks are evident with revelations of the recent coronavirus outbreak.  The risks are exacerbated by global travel and trade and lack of pandemic preparedness capability.

airPHX as an Effective Deterrent

airPHX technology provides a method of addressing GCBR risks in active public settings.   According to Dr. Rick Falkenberg, Ph.D., Scientific Air Solutions, in previously published independent research "Viruses possess higher capacity for genetic mutability due to both the structure of their genomes and the generation time for replication in which large numbers of progeny virus are created each day. Additionally, the inability of a virus to be countered with a broad-spectrum antiviral compared with bacteria, fungi, and parasites makes viruses the more likely cause of a GCBR. Within the viral class, RNA viruses merit special concern chiefly because of their higher mutability compared to DNA viruses. Treatment via the airPHX system attacks the virus and bacterial cell wall allowing for complete destruction and no further RNA/DNA resistance mutation."  For More Information: https://bioaccent.org/microbiology/microbiology36.php

About airPHX

airPHX is a private company offering continuous, scalable, fully organic surface and air sanitization solutions without chemicals or UV radiation.  Installations include U.S. hospitals, other medical and healthcare facilities, U.S. government facilities, public buildings and schools.

SOURCE airPHX


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: